Former CytoDyn executives convicted of securities fraud

In recent news, two former officials of CytoDyn, a Washington State-based company, were found guilty of securities fraud. This comes after a federal jury in Maryland determined that Nader Pourhassan, the former president and CEO, engaged in deceptive practices relating to the company’s development pipeline, specifically regarding leronlimab—an investigational antibody for HIV and COVID-19.

Alongside Pourhassan, Kazem Kazempour, who served as CEO of Amarex Clinical Research during the scheme period from 2018 to 2021, was also convicted of a similar offense. Amarex Clinical Research is a Maryland-based contract research organization that was crucial for running CytoDyn’s clinical trials and liaising with the FDA.

The trial brought to light evidence that Pourhassan and Kazempour misled investors about CytoDyn’s clinical trials and regulatory submissions to the FDA. For instance, in 2020, they falsely claimed to shareholders that they had completed a regulatory application for leronlimab in HIV, when in reality, the submission was incomplete and unreviewable.

Furthermore, the former officials provided inaccurate information regarding the results of clinical trials for leronlimab in treating COVID-19, as well as its prospects of approval. The jury determined that Pourhassan was aware of the failure of leronlimab’s studies and the unlikelihood of approval, yet continued to deceive investors.

This verdict reflects the serious consequences of misleading investors and manipulating stock prices through false representations. It serves as a reminder of the importance of transparency and honesty in the financial and healthcare sectors. For more detailed information, you can read the full article on BioSpace.